Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

被引：0
作者：
Catriona Jamieson
Robert Hasserjian
Jason Gotlib
Jorge Cortes
Richard Stone
Moshe Talpaz
Jürgen Thiele
Scott Rodig
Olga Pozdnyakova
机构：
[1] Moores UC San Diego Cancer Centre,Department of Pathology
[2] Massachusetts General Hospital,Division of Hematology
[3] Stanford University School of Medicine/Stanford Cancer Institute,Division of Cancer Medicine, Department of Leukemia
[4] University of Texas MD Anderson Cancer Center,Department of Pathology
[5] Dana-Farber Cancer Institute,undefined
[6] The University of Michigan Hospital and Health Systems,undefined
[7] Comprehensive Cancer Center,undefined
[8] Institute of Pathology,undefined
[9] University of Cologne,undefined
[10] Brigham and Women’s Hospital,undefined
来源：
Journal of Translational Medicine | / 13卷
关键词：
Fibrosis; Janus kinase inhibitor; Myelofibrosis; Myeloproliferative neoplasms; Philadelphia chromosome-negative;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
    Jamieson, Catriona
    Hasserjian, Robert
    Gotlib, Jason
    Cortes, Jorge
    Stone, Richard
    Talpaz, Moshe
    Thiele, Juergen
    Rodig, Scott
    Pozdnyakova, Olga
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [2] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    Pardanani, A.
    Tefferi, A.
    Jamieson, C.
    Gabrail, N. Y.
    Lebedinsky, C.
    Gao, G.
    Liu, F.
    Xu, C.
    Cao, H.
    Talpaz, M.
    BLOOD CANCER JOURNAL, 2015, 5 : e335 - e335
  • [3] Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib
    Saha, Chandan
    Harrison, Claire
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 583 - 595
  • [4] Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naive and exposed patients with myelofibrosis
    England, James T.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (15) : 1677 - 1686
  • [5] Effect of Food on the Bioavailability and Tolerability of the JAK2-Selective Inhibitor Fedratinib (SAR302503): Results From Two Phase I Studies in Healthy Volunteers
    Zhang, Meng
    Xu, Christine
    Ma, Lei
    Shamiyeh, Elias
    Yin, Jianyun
    von Moltke, Lisa L.
    Smith, William B.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (04): : 315 - 321
  • [6] Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
    Harrison, Claire N.
    Schaap, Nicolaas
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Verstovsek, Srdan
    Rose, Shelonitda
    Zhang, Jun
    Sy, Oumar
    Mesa, Ruben A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 317 - 327
  • [7] Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with α-interferon
    Domingues, MA
    Hæpers, ATC
    Massaut, IHB
    Vassallo, J
    Lorand-Metze, I
    HAEMATOLOGICA, 1998, 83 (12) : 1124 - 1125
  • [8] Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
    Nakaya, Y.
    Shide, K.
    Naito, H.
    Niwa, T.
    Horio, T.
    Miyake, J.
    Shimoda, K.
    BLOOD CANCER JOURNAL, 2014, 4 : e174 - e174
  • [9] Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman, Guido
    Mascarenhas, John
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (01) : 23 - 28
  • [10] MOMELOTINIB HYDROCHLORIDE JAK1/JAK2 inhibitor Treatment of myelofibrosis Treatment of pancreatic cancer
    Price, S.
    George, T.
    Pinilla-Ibarz, J.
    DRUGS OF THE FUTURE, 2015, 40 (09) : 561 - 568
12345